Press Releases

Month Year

Get News Alerts by Email

Jul 30, 2025

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
Jul 30, 2025

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease

Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with...
- Photos 1
Jul 30, 2025

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease 56% of Patients with Low Tau Continued to Demonstrate...
- Photos 1
Jul 21, 2025

Eisai to Present Four-Year Efficacy and Safety Data on Continuous Treatment With Lecanemab at the Alzheimer's Association International Conference 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...
May 20, 2025

Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025

Long-Term Follow-Up Data from LEAP-002 Offers Insights into Hepatocellular Carcinoma Treatment Pipeline Data in Endometrial Carcinoma Among Studies to be Presented NUTLEY, N.J., May 20, 2025...

Show per page

Open a printable version of this page
Email the URL of this page to a friend